Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis.
Cuétara
M S
MS
Aguilar
A
A
Martin
L
L
Aspiroz
C
C
del Palacio
A
A
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003881:Dermatomycoses / Q000150:complications; D003875:Drug Eruptions / Q000209:etiology* / Q000382:microbiology; D000069347:Erlotinib Hydrochloride; D005499:Folliculitis / Q000139:chemically induced* / Q000382:microbiology; D006801:Humans; D008290:Malassezia / Q000302:isolation & purification; D008297:Male; D011799:Quinazolines / Q000009:adverse effects*; D012393:Rosacea / Q000139:chemically induced* / Q000382:microbiology
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride